Regeneron Pharmaceuticals, Inc. - Common Stock (REGN)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 2, 2026Investment Snapshot
- Trading 34% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 15.4% — good return on equity
Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $78.9 billion . Key value metrics: P/E ratio 16.2, P/B ratio 2.49, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Regeneron Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) is currently trading 34% above its Graham Number of $570.42, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.2x.
On financial health, REGN shows a moderate Piotroski F-Score of 5/9, and solid return on equity of 15.4% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for REGN is 77/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
REGN shows revenue growing at 1% year-over-year, with earnings growing at 2%.
REGN pays a modest dividend yield of 0.5%.